These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 21087119

  • 1. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.
    Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119
    [Abstract] [Full Text] [Related]

  • 2. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C.
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [Abstract] [Full Text] [Related]

  • 3. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 4. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 5. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
    Ainsworth MA, Bendtzen K, Brynskov J.
    Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
    [Abstract] [Full Text] [Related]

  • 6. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
    Imaeda H, Andoh A, Fujiyama Y.
    J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A, Asher R, Jackson R, Sager K, Martin K, Kneebone A, Philips S, Taylor W, Subramanian S.
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
    [Abstract] [Full Text] [Related]

  • 11. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
    Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A.
    Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737
    [Abstract] [Full Text] [Related]

  • 12. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

  • 13. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 14. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 15. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP.
    Clin Immunol; 2006 Jan 13; 118(1):11-9. PubMed ID: 16125467
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity of infliximab: how to handle the problem?
    Baert F, De Vos M, Louis E, Vermeire S, Belgian IBD Research Group.
    Acta Gastroenterol Belg; 2007 Jan 13; 70(2):163-70. PubMed ID: 17715629
    [Abstract] [Full Text] [Related]

  • 17. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.
    J Crohns Colitis; 2013 Oct 13; 7(9):736-43. PubMed ID: 23200919
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A, Straathof JW, Derijks LJ.
    Eur J Gastroenterol Hepatol; 2015 Mar 13; 27(3):242-8. PubMed ID: 25569569
    [Abstract] [Full Text] [Related]

  • 19. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.
    J Crohns Colitis; 2015 Mar 13; 9(3):238-45. PubMed ID: 25576753
    [Abstract] [Full Text] [Related]

  • 20. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A.
    Aliment Pharmacol Ther; 2004 Nov 15; 20(10):1143-52. PubMed ID: 15569117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.